Neuraxis, INC
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
NRXS$6.25-5.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2023
Balance Sheets
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $3,696,870 | $78,560 |
| Accounts receivable, net of credit losses of $5,000 and $11,993 as of December 31, 2024 and 2023, respectively | 244,618 | 73,167 |
| Inventories, net of reserves of $4,454 and $0 as of December 31, 2024 and 2023, respectively | 44,328 | 21,220 |
| Prepaids and other current assets | 280,367 | 69,663 |
| Total current assets | 4,266,183 | 242,610 |
| Property and Equipment, at cost: | 464,402 | 436,626 |
| Less - accumulated depreciation | (374,420) | (348,074) |
| Property and equipment, net | 89,982 | 88,552 |
| Other Assets: | ||
| Operating lease right of use asset, net | 284,656 | 70,263 |
| Intangible assets, net | 96,588 | 108,073 |
| Security deposit | 20,163 | — |
| Total Assets | $4,757,572 | $509,498 |
Balance Sheets
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Liabilities | ||
| Current Liabilities: | ||
| Accounts payable | $596,946 | $1,204,219 |
| Accrued expenses | 1,577,780 | 401,088 |
| Notes payable | 154,152 | 148,062 |
| Current portion of operating lease payable | 62,754 | 49,127 |
| Customer deposits | 32,527 | 74,947 |
| Warrant liabilities | 9,166 | 8,225 |
| Total current liabilities | 2,433,325 | 1,885,668 |
| Non-current Liabilities: | ||
| Operating lease payable, net of current portion | 256,499 | 27,071 |
| Total non-current liabilities | 256,499 | 27,071 |
| Total liabilities | 2,689,824 | 1,912,739 |
| Commitments and contingencies (see note 16) | - | - |
| Stockholders’ Equity (Deficit) | ||
| Convertible Series B Preferred stock, $0.01 par value; 5,000,000 and 0 shares authorized, 4,280,939 and 0 shares issued and outstanding as of December 31, 2024 and 2023, respectively | 4,281 | — |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 6,990,227 and 6,508,897 issued and outstanding as of December 31, 2024 and 2023, respectively | 6,990 | 6,509 |
| Additional paid in capital | 58,856,089 | 47,148,361 |
| Accumulated deficit | (56,799,612) | (48,558,111) |
| Total stockholders’ equity (deficit) | 2,067,748 | (1,403,241) |
| Total Liabilities and Stockholders’ Equity (Deficit) | $4,757,572 | $509,498 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.